• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
AZD-8330

AZD-8330

Product ID A9715
Cas No. 869357-68-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $155.00 In stock
5 mg $392.10 In stock
10 mg $629.00 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

AZD-8330 is an inhibitor of MEK1/2 that exhibits anticancer chemotherapeutic activity. AZD-8330 is currently in clinical trials for the treatment of advanced stage cancers.

Product Info

Cas No.

869357-68-6

Purity

≥98%

Formula

C16H17FlN3O4

Formula Wt.

461.23

IUPAC Name

2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide

Synonym

ARRY-704, ARRY-424704

Solubility

DMSO 92 mg/mL (199.46 mM) Ethanol 92 mg/mL (199.46 mM) Water Insoluble

Appearance

White Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

A9715 MSDS PDF

Info Sheet

A9715 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Cohen RB, Aamdal S, Nyakas M, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. PMID: 23433846.

Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. PMID: 23587417.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A5162

    Amprolium Hydrochloride

    Thiamine, coccidiostat; thiamine transporter in...

    ≥97%
  • S6018

    Spectinomycin Dihydrochloride Pentahydrate

    Aminocyclitol; protein synthesis inhibitor.

    ≥603 µg/mg (potency)
  • O4533

    Oligomycin

    Mixture of oligomycins A, B, C; oxidative phosp...

    ≥97%
  • Z5653

    Zonisamide

    Sulfonamide; carbonic anhydrase inhibitor, volt...

    ≥96%
  • A2054

    Aflatoxin M2

    Mycotoxin produced by species of Aspergillus; D...

    ≥98%
  • O2145

    Ofloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • D5690

    Doxazosin Mesylate

    Quinazoline; α1-adrenergic antagonist.

    ≥98%
  • O938582

    41-Oxo-rapamycin

    Impurity of rapamycin

    ≥95%
  • E6896

    Erysolin

    ITC found in cruciferous vegetables, analog of ...

    ≥97%
  • B8278

    Butoconazole Nitrate

    Imidazole; 14-α demethylase inhibitor.

    ≥98%
  • E9417

    Exendin-4

    Peptide, GLP-1 analog found in Heloderma; GLP-1...

    ≥95%
  • T7156

    Tropisetron Hydrochloride

    α7 nAChR partial agonist, 5-HT3 antagonist.

    ≥98%
  • L5870

    Lornoxicam

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • T3461

    Tiplaxtinin

    PAI-1 inhibitor.

    ≥98%
  • B0245

    Balicatib

    Cathepsin K inhibitor.

    ≥98%
  • C9809

    Cyclopiazonic Acid

    SERCA inhibitor.

    ≥98%, TLC
  • F1652

    Fenbufen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • C9673

    Cysteamine Hydrochloride

    Aminothiol, CoA component; ulcer inducer.

    ≥99%
  • N6272

    NPS-2143 Hydrochloride

    Ca2+-sensing receptor antagonist.

    ≥99%
  • L1628

    Ac-LEHD-pNa

    Caspase 9 substrate.

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only